Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Long-Term Deferred Tax data on file, last reported at $59.4 million in Q4 2025.

• In Q4 2025, Long-Term Deferred Tax rose 94.19% year-over-year to $59.4 million; the TTM figure through Dec 2025 stood at $59.4 million (up 94.19% YoY), while the FY2025 annual figure was $59.4 million, up 105.23% from the prior year.
• Long-Term Deferred Tax advanced to $59.4 million in Q4 2025, from $30.6 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $59.4 million in Q4 2025 and bottomed at $13.3 million in Q4 2023.
• A 3-year average of $34.4 million and a median of $30.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 129.56% — and 2025, when it jumped 94.19%.
• Year by year, Long-Term Deferred Tax stood at $13.3 million in 2023, then jumped by 129.56% to $30.6 million in 2024, then surged by 94.19% to $59.4 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $59.4 million (Q4 2025), $30.6 million (Q4 2024), and $13.3 million (Q4 2023), per Business Quant data.

Peer Comparison